# An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

> **NCT02596035** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 197 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02596035
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-08
- **Primary completion:** 2018-03-19
- **Final completion:** 2021-05-24
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596035, "An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02596035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*